Evaluating the Efficacy of Oral Semaglutide in Chinese Patients with Type 2 Diabetes by Baseline Characteristics-Post Hoc Analysis of PIONEER 11 and 12

被引：0
|
作者：
Ji, Linong
Yuan, Guoyue
Liu, Jun
Zhang, Bingjie
Liu, Wenyan
Shen, Zewei
机构：
来源：
DIABETES | 2024年 / 73卷
关键词：
D O I：
10.2337/db24-752-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
752-P
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes: A subgroup analysis by baseline variables in the PIONEER 9 and PIONEER 10 trials
    Yabe, Daisuke
    Deenadayalan, Srikanth
    Horio, Hiroshi
    Kaneto, Hideaki
    Jensen, Thomas Bo
    Terauchi, Yasuo
    Yamada, Yuichiro
    Inagaki, Nobuya
    JOURNAL OF DIABETES INVESTIGATION, 2022, 13 (06) : 975 - 985
  • [2] Efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes: A post hoc subgroup analysis of the PIONEER 1, 3, 4 and 8 trials
    Araki, Eiichi
    Terauchi, Yasuo
    Watada, Hirotaka
    Deenadayalan, Srikanth
    Christiansen, Erik
    Horio, Hiroshi
    Kadowaki, Takashi
    DIABETES OBESITY & METABOLISM, 2021, 23 (12): : 2785 - 2794
  • [3] Efficacy and safety of oral semaglutide by baseline age in Japanese patients with type 2 diabetes: A subgroup analysis of the PIONEER 9 and 10 Japan trials
    Yamada, Yuichiro
    Yabe, Daisuke
    Hertz, Christin Loth
    Horio, Hiroshi
    Nakamura, Jiro
    Nielsen, Anne Moller
    Seino, Yutaka
    DIABETES OBESITY & METABOLISM, 2022, 24 (02): : 321 - 326
  • [4] Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial
    Bain, Stephen C.
    Mosenzon, Ofri
    Arechavaleta, Rosario
    Bogdanski, Pawel
    Comlekci, Abdurrahman
    Consoli, Agostino
    Deerochanawong, Chaicharn
    Dungan, Kathleen
    Faingold, Maria C.
    Farkouh, Michael E.
    Franco, Denise R.
    Gram, Jeppe
    Guja, Cristian
    Joshi, Pankaj
    Malek, Rachid
    Merino-Torres, Juan F.
    Nauck, Michael A.
    Pedersen, Sue D.
    Sheu, Wayne H. -H.
    Silver, Robert J.
    Tack, Cees J.
    Tandon, Nikhil
    Jeppesen, Ole K.
    Strange, Mette
    Thomsen, Mette
    Husain, Mansoor
    DIABETES OBESITY & METABOLISM, 2019, 21 (03): : 499 - 508
  • [5] Semaglutide Reduces Mace Consistently Across Baseline Triglyceride Levels in Patients With Type 2 Diabetes: A Post Hoc Analysis of the Sustain 6 and Pioneer 6 Trials
    Verma, Subodh
    Leiter, Lawrence A.
    Michelsen, Marie M.
    Orsted, David
    Rasmussen, Soren
    Bhatt, Deepak L.
    CIRCULATION, 2020, 142
  • [6] Impact of baseline characteristics on the efficacy of once-weekly subcutaneous semaglutide among participants with type 2 diabetes: A post hoc analysis of SUSTAIN China
    Ji, Linong
    Lu, Yibing
    Shen, Zewei
    Hu, Ping
    Liu, Wenyan
    Zhang, Qiu
    Shi, Bimin
    DIABETES OBESITY & METABOLISM, 2024,
  • [7] Efficacy and Safety of Dulaglutide by Baseline HbA1c in Chinese Patients with Type 2 Diabetes: A Post Hoc Analysis
    Miao Yu
    Guo Yue Yuan
    Bin Zhang
    Hai Ya Wu
    Xiao Feng Lv
    Diabetes Therapy, 2020, 11 : 1147 - 1159
  • [8] Efficacy and Safety of Dulaglutide by Baseline HbA1c in Chinese Patients with Type 2 Diabetes: A Post Hoc Analysis
    Yu, Miao
    Yuan, Guo Yue
    Zhang, Bin
    Wu, Hai Ya
    Lv, Xiao Feng
    DIABETES THERAPY, 2020, 11 (05) : 1147 - 1159
  • [9] EFFICACY AND SAFETY OF ORAL SEMAGLUTIDE IN RUSSIAN PATIENTS WITH TYPE 2 DIABETES: SUBGROUP ANALYSIS OF PIONEER 1, 2, 3 TRIALS
    Shamkhalova, Minara Sh
    Shestakova, Marina, V
    DIABETES MELLITUS, 2022, 25 (03): : 204 - 214
  • [10] Glycaemic variability of oral semaglutide vs empagliflozin: a post-hoc analysis of PIONEER 2
    Montanya, E.
    Abildlund, M. T.
    Kreiner, E. B.
    Mosenzon, O.
    Rosenlund, S.
    Vilsboll, T.
    DIABETOLOGIA, 2021, 64 (SUPPL 1) : 257 - 257
12345